Ironwood Pharmaceuticals, Inc.
$4.42
▼
-9.23%
2026-04-21 07:36:00
ironwoodpharma.com
NMS: IRWD
Explore Ironwood Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$719.09 M
Current Price
$4.42
52W High / Low
$5.78 / $0.53
Stock P/E
29.94
Book Value
$-1.61
Dividend Yield
—
ROCE
76.78%
ROE
-8.53%
Face Value
—
EPS
$0.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
100
Beta
0.17
Debt / Equity
-2.28
Current Ratio
1.13
Quick Ratio
1.13
Forward P/E
2.49
Price / Sales
2
Enterprise Value
$974.25 M
EV / EBITDA
8.08
EV / Revenue
3.29
Rating
None
Target Price
$6.1
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
Cons
- Return on equity is on the weaker side.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cumberland Pharmaceuticals Inc. | $3.15 | — | $47.57 M | — | -6.97% | -12.17% | $6.27 / $1.85 | $1.66 |
| 2. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 3. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 4. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 5. | Rockwell Medical, Inc. | $0.94 | — | $37.03 M | — | -9.86% | -15.28% | $2.1 / $0.78 | $0.94 |
| 6. | Liquidia Corporation | $37.66 | — | $3.32 B | — | -26.74% | -1.11% | $46.67 / $11.85 | $0.51 |
| 7. | IM Cannabis Corp. | $0.41 | — | $3.13 M | — | 510.44% | -516.26% | $9.7 / $1.75 | $-0.45 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 47.71 M | 122.06 M | 85.24 M | 41.14 M | 90.55 M | — |
| Operating Profit | 6.55 M | 77.68 M | 45.07 M | -10.55 M | 31.56 M | — |
| Net Profit | -2.28 M | 40.08 M | 23.6 M | -37.39 M | 2.26 M | — |
| EPS in Rs | -0.01 | 0.25 | 0.14 | -0.23 | 0.01 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 296.15 M | 351.41 M | 442.74 M | 410.6 M |
| Operating Profit | 118.76 M | 95.72 M | 168.34 M | 250.34 M |
| Net Profit | 24.02 M | 0.88 M | -1 B | 175.06 M |
| EPS in Rs | 0.15 | 0.01 | -6.15 | 1.07 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 396.9 M | 350.91 M | 471.07 M | 1.1 B |
| Total Liabilities | 658.74 M | 652.24 M | 817.37 M | 448.14 M |
| Equity | -261.83 M | -301.33 M | -346.3 M | 652.38 M |
| Current Assets | 274.18 M | 182.37 M | 233.29 M | 780.63 M |
| Current Liabilities | 242.22 M | 38.85 M | 276.1 M | 25.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 127.04 M | 103.55 M | 183.43 M | 273.76 M |
| Investing CF | -0.03 M | -0.14 M | -1.03 B | -0.14 M |
| Financing CF | 0.22 M | -106.97 M | 277.16 M | -237.55 M |
| Free CF | 127.01 M | 103.41 M | 183.15 M | 273.63 M |
| Capex | -0.03 M | -0.14 M | -0.27 M | -0.14 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -20.63% | 7.83% | — | — |
| Earnings Growth % | 100.09% | -672.5% | — | — |
| Profit Margin % | 0.25% | -226.37% | 42.64% | — |
| Operating Margin % | 27.24% | 38.02% | 60.97% | — |
| Gross Margin % | — | — | 100% | — |
| EBITDA Margin % | 28.53% | -208.9% | 63.67% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.